DIRECT ADMIN REP DEFIC ADGVVEGF121.10 W/VEGF121CDNA TO ISCH MYOCARADIUM

直接管理代表 DEFIC ADGVVEGF121.10 W/VEGF121CDNA 至 ISCH 心肌

• 批准号: 6275274
• 负责人: RONALD G CRYSTAL
• 金额: $ 5.51万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275274
• 关键词: blood vessels; clinical research; clinical trials; collateral circulation; gene therapy; genetic transduction; heart circulation; heart function; human subject; human therapy evaluation; myocardial ischemia /hypoxia; transfection /expression vector; vascular endothelial growth factors

The focus of this protocol is to evaluate the adenoviral delivery of vascular endothelial growth factor (VEGF) directly to ischemic myocardium. The objectives are: (1) to determine the dose-dependent safety/toxicity of direct administration of the vector AdGVVEGF121.10 to the ischemic myocardium, (2) to demonstrate whether direct administration of AdGVVEGF121.10 to the myocardium will induce growth of collateral blood vessels, improve coronary blood flow and improve cardiac function in the region of ischemia.

该方案的重点是评估腺病毒递送 血管内皮生长因子(VEGF)直接作用于缺血心肌。 其目的是：(1)确定药物的剂量依赖性安全性/毒性。 载体AdGVVEGF121.10对脑缺血的直接给药 心肌，(2)证明直接给药是否 AdGVVEGF121.10作用于心肌可诱导侧支循环血的生长 改善冠脉血流量，改善心功能 缺血区。